Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Gilead SciencesXTER:GIS -0.02%80 3-1 Month Momentum % is 7.37% as of Sep. 10, 2026. GuruFocus rates XTER:GIS with a GF Score™ of 80/100 and a GF Value™ of €92.89 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,028 Drug Manufacturers companies, Gilead Sciences ranks better than 62.84% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-10), Gilead Sciences's 3-1 Month Momentum % is 7.37%.
The industry rank for Gilead Sciences's 3-1 Month Momentum % or its related term are showing as below:
XTER:GIS's 3-1 Month Momentum % is ranked better than 62.84% of 1028
companies
in the Drug Manufacturers industry
Industry Median: 2.22
vs XTER:GIS: 7.37
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Gilead Sciences 3-1 Month Momentum % Related Terms
XTER:GIS vs PFE, BMY, AMGN: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - General subindustry, Gilead Sciences's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gilead Sciences 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Gilead Sciences's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gilead Sciences (XTER:GIS) has a 3-1 Month Momentum % of 7.37% as of Sep. 10, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Gilead Sciences and its competitors. According to the industry distribution chart, Gilead Sciences ranks #382 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 37.2%.
Is Gilead Sciences' 3-1 Month Momentum % too high?
Gilead Sciences' current 3-1 Month Momentum % is 7.37%. The Drug Manufacturers industry median 3-1 Month Momentum % is 2.22. Gilead Sciences' value of 7.37% is 232% above this industry median. Based on the distribution chart, Gilead Sciences ranks #382 out of 1028 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Gilead Sciences has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' 3-1 Month Momentum % compare to PFE and BMY?
According to the Drug Manufacturers industry distribution chart, Gilead Sciences ranks #382 out of 1028 companies for 3-1 Month Momentum %. This puts Gilead Sciences in the upper half of its industry. The industry median 3-1 Month Momentum % is 2.22. Gilead Sciences' value of 7.37% is 232% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
The median 3-1 Month Momentum % among Drug Manufacturers companies is 2.22, based on 1,028 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gilead Sciences's current 3-1 Month Momentum % of 7.37% is 232% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Gilead Sciences and its competitors. For the Drug Manufacturers industry, the median 3-1 Month Momentum % is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gilead Sciences's current 3-1 Month Momentum % is 7.37%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Based on GuruFocus' analysis, Gilead Sciences (XTER:GIS) is currently considered Significantly Overvalued. The stock's GF Value™ is €92.89, compared to a current price of €125.90 — trading 35.5% above its estimated fair value. The current 3-1 Month Momentum % is 7.37% and 232% above the Drug Manufacturers industry median of 2.22. Gilead Sciences' overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Gilead Sciences (XTER:GIS), the current 3-1 Month Momentum % is 7.37% as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Gilead Sciences (XTER:GIS) Overvalued in 2026?
Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued.
The current stock price of €125.90 is trading 35.5% above its estimated GF Value™ of €92.89.
GuruFocus considers Gilead Sciences to be Significantly Overvalued.
Key valuation signals for XTER:GIS:
3-1 Month Momentum %: 7.37%
GF Value™: €92.89 vs. price of €125.90 (35.5% above fair value)
Industry Position: 232% above the Drug Manufacturers median (#382 of 1028)
No single metric tells the full story. See the XTER:GIS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
80GF Score
Get the complete analysis for XTER:GIS
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:GIS has been successfully added to your 
